Abbott (NYSE:ABT) announced that its FreeStyle Libre 3 continuous glucose monitor (CGM) received UK authorization for use in automated insulin delivery.
Authorization enables FreeStyle Libre 3 — Abbott’s newest sensor — to work with the Ypsomed mylife YpsoPump and CamDiab’s CamAPS FX mobile app. The company called this a “major step forward” for type 1 diabetes management in the United Kingdom.
At the end of last year, the company received authorization to integrate FreeStyle Libre 3 with the mylife Loop from Ypsomed and CamDiab. That collaboration began in Germany. Abbott said at the time that it planned launches in the UK, Switzerland and the Netherlands in the first half of this year.
Combined, the technologies form an intelligent process to deliver insulin in the form of an artificial pancreas. The closed-loop system utilizes real-time glucose data to create an automated insulin delivery (AID) system. It removes the guesswork of insulin dosing and helps people with type 1 diabetes improve quality of life and reach better treatment targets.
In March, the FDA cleared the FreeStyle Libre 2 and FreeStyle Libre 3 for AID integration. Abbott said that, in addition to this partnership, it’s looking to make FreeStyle Libre interoperable with other leading insulin delivery systems.
Get the full story at our sister site, Drug Delivery Business News.